BRAXX Biotech Co., Ltd.’s Post

I knew I should have worn a jacket! Thanks again to Faron for inviting us along to speak at their capital markets day and present our work on payer interviews, KOL interviews and epi forecasting. If you want to watch the presentation you can see it in the link below. #biotech #marketresearch #pricing #forecasting PharmaVentures

Just a quick bump for Ralph Hughes who has been doing a great job building out our pricing and market access practice. He recently presented some of their work at Faron's recently capital markets day. Jacket or no jacket, its a good piece of analysis on the potential of #Bexmarilimab in MDS. #marketaccess #mds #biotech #marketresearch

Enavate Sciences is proud to invest in Aviceda Therapeutics’ $207.5 million Series C financing. This funding will support Aviceda’s ongoing Phase 2b/3 trial in geographic atrophy and a planned pivotal Phase 3 trial, marking a critical milestone in bringing more efficacious therapies to GA patients. #GeographicAtrophy https://lnkd.in/etkZEXfW

Ozempic rival, Verdiva Bio, cofounded by Khurem Farooq, has launched a $411 million Series A financing round to develop innovative therapies for obesity and cardiometabolic disorders. The oversubscribed round was co-led by Forbion and General Atlantic, with participation from prominent healthcare investors, including RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures 礼来亚洲基金, and LYFE Capital. This funding will advance the clinical development of existing assets and expand the company’s cardiometabolic portfolio. Read the announcement in the news section on colaeb.com

Excited to share that I'll be joining the World CDx and Liquid Biopsy Summit as a panel discussant in just 3 weeks! This premier event brings together thought leaders to explore the evolving landscape of Companion Diagnostics. Looking forward to exchanging insights with industry leaders and experts on the latest advancements in CDx. If you're attending, let's connect! Would love to hear your thoughts and perspectives. #WorldCDxSummit #CompanionDiagnostics #PrecisionMedicine #HealthcareInnovation #HealthcareLeadership

"We've demonstrated the drug is antifibrotic. We know that it works, and that's a considerable step forward." – Gary Phillips, CEO In a recent update, our CEO Gary Phillips shared promising insights from our earlier study in myelofibrosis patients who had failed on JAK inhibitors. In these challenging cases, almost half of the patients experienced a reduction in bone marrow fibrosis, with many showing stable or improved blood counts and symptom relief. As we move forward with patients earlier in their treatment journey, we’re extending our current study to 12 months, aiming to demonstrate even greater clinical benefits. With a solid safety profile and encouraging signs of efficacy. #Syntara #SNT #Myelofibrosis #SNT5505 #ClinicalTrials #Biotech #Innovation #BloodCancer

I'm pleased to announce that Accelerator Life Science Partners portfolio companies Automera, Proniras Corporation, and Kayothera will be represented at #JPMHC2025 - the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco this January. These companies exemplify innovation and are advancing science in critical therapeutic areas: Automera recently closed $16M in Series A funding to propel its pioneering autophagy-targeting chimera platform. Proniras Corporation has begun enrolling patients in its Phase 1 study of Tezampanel for the treatment of opioid withdrawal, marking an important step in addressing substance use disorders. Kayothera is progressing KAYO-1609, the first retinoid pathway inhibitor to enter IND-enabling studies, offering new hope in oncology. If you’ll be attending #JPM2025 (January 13–16) and would like to connect with these companies, please reach out via LinkedIn. Accelerator Life Science Partners remains steadfast in its commitment to advancing transformative solutions that address some of the most pressing challenges in healthcare. #jpmhc2025 #biotech #healthcareinnovation

We are excited to announce our participation in Aviceda Therapeutics’ $207.5M Series C financing round. Aviceda’s lead program, AVD-104, is advancing through pivotal trials for geographic atrophy (GA), and with Phase 2b/3 data anticipated in late 2025, AVD-104 has the potential to transform GA treatment and address a significant unmet need. We are thrilled to be partnering with Board Chair Dr. David Guyer and an outstanding group of investors, led by Omega Funds and TCGX, as Aviceda works to improve outcomes for patients with GA. https://lnkd.in/eikDqZPa

🚀 Mesoblast Secures Major Funding for Ryoncil’s Commercial Launch Mesoblast Limited (ASX: MSB) has successfully raised AU$260 million through a global private placement, priced at AU$2.50 per share. This achievement, backed by key shareholders in the US, UK, and Australia, paves the way for the US commercial launch of Ryoncil, a breakthrough treatment for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD). The funds will also accelerate a pivotal Phase 3 clinical trial for chronic low back pain, expand manufacturing capacity, and support corporate initiatives. Dr. Silviu Itescu, Mesoblast’s CEO, highlighted this as a transformative step, scaling the production of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, to address life-threatening conditions. 🌍💊 #InnovationInHealthcare #BiotechBreakthrough #Ryoncil #Mesoblast * Click here to subscribe for free 7-day access to our daily market insights and analysis: https://lnkd.in/gzhTXvNT

Did you miss it? 👀 Find out about the newly launched imaging suite and advanced lung Fibroblast-to-Myofibroblast Transition (FMT) assay. Comprising high-content and high-throughput equipment, the state-of-the-art imaging suite provides more in-depth and robust in vitro data. The advanced high-throughput high-sensitivity lung FMT assay facilitates rapid assessment of the efficacy of anti-fibrotic drug candidates enabling easy screening of libraries of compounds. 💬 “The launch of our new imaging suite and accompanying assay is a key step in continuing to provide innovative, market-leading in vitro models that advance the discovery and safe development of new drugs." - Dr Mike Nicholds, CEO and Co-Founder Learn more about our exciting new launch here: https://lnkd.in/gNBAEP3e #Newcells #DrugDevelopment #FMT #InVitroData